Orchid Pharma has entered into a manufacturing sublicense agreement with Global Antibiotic Research & Development Partnership (GARDP) to manufacture Cefiderocol- an antibiotic to treat certain Gram-negative infections.
This agreement is a critical step in an ambitious project by Shionogi & Co. (Shionogi), GARDP, and the Clinton Health Access Initiative (CHAI) that aims to provide access to Cefiderocol in a number of predominantly low and middle-income countries.
Orchid Pharma, established as an export-oriented unit (EOU), is a vertically integrated company spanning the entire pharmaceutical value chain from discovery to delivery with established credentials in research, manufacturing and marketing.
